Page last updated: 2024-09-04

moxifloxacin and Tuberculosis, Pulmonary

moxifloxacin has been researched along with Tuberculosis, Pulmonary in 110 studies

Research

Studies (110)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.91)	18.2507
2000's	25 (22.73)	29.6817
2010's	64 (58.18)	24.3611
2020's	20 (18.18)	2.80

Authors

Authors	Studies
Andries, K; Chauffour, A; Ibrahim, M; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA	1
Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L	1
Chaisson, RE; Dooley, K; Dorman, SE; Flexner, C; Hackman, J; Nuermberger, E; Peloquin, CA	1
Angulo-Barturen, I; Beltrán, M; Cáceres, N; Cardona, PJ; García, JI; García-Bustos, JF; Rullas, J	1
Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J	1
Bin, W; Chen, S; Ding, CZ; Franzblau, SG; Hu, Y; Huang, Z; Jiang, N; Luo, W; Shen, L; Tao, X; Wei, X; Wei, Y; Xu, D; Yang, M; Zhu, Y	1
Allen, L; Carr, W; Goswami, N; Kurbatova, E; Starks, A; Winston, C	1
Beraldi-Magalhães, F; Fernandez-Llimos, F; Imazu, P; Pontarolo, R; Santos, JM; Tonin, FS	1
Chi, Z; Pan, X; Tang, W; Yin, Y; Zhao, M	1
Borana, H; Deokar, K; Desai, G; Purohit, G; Yogi, S	1
Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z	1
Gao, M; Guo, Y; Huo, F; Jia, J; Jiang, H; Li, W; Ma, H; Qin, L; Wu, X; Xue, Y; Yin, J; Zhu, C	1
He, Y; Li, X	1
Berry, C; Dodd, M; du Cros, P; Fielding, K; Kazounis, E; Liverko, I; McHugh, TD; Moodliar, R; Moore, DAJ; Motta, I; Ngubane, N; Nyang'wa, BT; Parpieva, N; Rassool, M; Ritmeijer, K; Solodovnikova, V; Spigelman, M; Tigay, Z	1
Aarnoutse, R; Boeree, M; Cho, YL; Dierig, A; Geiter, L; Gong, X; Heinrich, N; Hoelscher, M; Hoffmann, L; Jarchow-MacDonald, A; Liyoyo, A; Mbeya, B; McHugh, TD; Mhimbira, FA; Minja, LT; Mpagama, S; Ntinginya, N; Phillips, P; Rassool, M; Schultz, S; Sebe, M; Svensson, EM; Te Brake, L; Wallis, RS; Wildner, LM	1
Aarnoutse, R; Boeree, M; Dombay, E; Eldirdiri, S; Gillespie, SH; Heinrich, N; Hoelscher, M; Kibiki, GS; Mtafya, B; Musisi, E; Ntinginya, NE; Sabiiti, W; Wyness, A	1
Aljayyoussi, G; Ardrey, A; Biagini, GA; Donnellan, S; Martinez-Rodriguez, C; Moyo, E; Ward, SA	1
Furin, J; McKenna, L	1
Bozeman, L; Burman, WJ; Chaisson, RE; Chang, KC; Chen, M; Cotton, M; Dooley, KE; Dorman, SE; Engle, M; Feng, PJ; Fletcher, CV; Goldberg, SV; Ha, P; Heilig, CM; Johnson, JL; Kurbatova, EV; Lessem, E; Metchock, B; Miro, JM; Nahid, P; Nhung, NV; Pettit, AC; Phillips, PPJ; Podany, AT; Purfield, AE; Robergeau, K; Samaneka, W; Scott, NA; Sizemore, E; Swindells, S; Vernon, A; Weiner, M	1
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A	1
Guan, Y; Liu, Y	1
Akhtar, SM; Kaur, H; Mittal, GK; Reddy, VASK	1
Qiujing, F; Weiwei, W	1
Fan, J; Sun, M	1
Bryant, K; Chaisson, RE; Dooley, KE; Dorman, SE; Engle, M; Goldberg, SV; Hakim, J; Johnson, JL; Kurbatova, EV; Lourens, M; Martinson, NA; Muzanyi, G; Nahid, P; Narunsky, K; Nerette, S; Nguyen, NV; Pham, TH; Phan, HTT; Phillips, PPJ; Pierre, S; Purfield, AE; Samaneka, W; Sanne, I; Savic, RM; Scott, NA; Shenje, J; Sizemore, E; Swindells, S; Vernon, A; Waja, Z; Weiner, M	1
Chen, W; Cheng, NC; Fang, G; Hu, CM; Huang, LL; Xie, WP	1
Chen, H; Chen, S; Wang, F; Wu, M; Xu, J; Xu, P; Zhu, X	1
Al-Hajoj, S; Varghese, B	1
Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S	1
Cohen, L; Guarner, J; Hunt, WR	1
Caylá, JA; García-Goez, JF; Miro, JM; Munera, GA; Pacheco, R; Rojas, V	1
Bablishvili, N; Bernheim, A; Blumberg, HM; Derendorf, H; Gogishvili, S; Guarner, J; Heinrichs, MT; Kempker, RR; Little, BP; Nikolaishvili, K; Peloquin, CA; Sabulua, I; Tukvadze, N; Vashakidze, S	1
Caminero Luna, JA; Cerezo Lajas, A; de Miguel Díez, J; Rodríguez Guzmán, MDC	1
Cavallaro, A; Das, SC; Doyle, C; Eedara, BB; Rangnekar, B; Sinha, S	1
Coates, AR; Davies, GR; Gillespie, SH; Hu, Y; Liu, Y; Pertinez, H	1
Amukoye, EI; Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; McHugh, TD; Mendel, CM; Meredith, SK; Murphy, ME; Murthy, SE; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD; Wills, GH	1
Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M	1
Alffenaar, JWC; Kosterink, JGW; Pranger, AD; van der Werf, TS	1
Arrey, F; Gengenbacher, M; Kaiser, P; Kaufmann, SHE; Krishnamoorthy, G; Kuhlmann, S; Löwe, D; Lozza, L; Maertzdorf, J; Moura-Alves, P; Nouailles, G; Skrahina, A; Skrahina, T	1
Govender, D; Naidoo, A; Naidoo, K; Padayatchi, N; Perumal, R; Yende-Zuma, N	1
Chiang, CY; Conradie, F; Dalai, D; Dat, PT; Lan, N; Master, I; Mebrahtu, T; Meredith, SK; Meressa, D; Moodliar, R; Ngubane, N; Nunn, AJ; Phillips, PPJ; Rusen, ID; Sanders, K; Squire, SB; Torrea, G; Tsogt, B; van Deun, A	1
Khalid, UK; Kumar Verma, A; Mathuria, KK; Munjal, S; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Vohra, V	1
Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA	1
Jiang, Y; Li, G; Li, M; Liu, H; Liu, Z; Wan, K; Wang, R; Xu, D; Xu, Z; Zhao, LL; Zhao, X	1
Dawson, R; Diacon, A	1
Balasubramanian, R; Banurekha, VV; Baskaran, D; Chandrasekar, C; Charles, N; Ganapathy, S; Gangadevi, NP; Iliayas, AS; Jagannath, K; Jawahar, MS; Kumar, MM; Kumar, SR; Kumar, V; Mohan, V; Narayanan, PR; Paramasivan, CN; Parthasarathy, RT; Ponnuraja, C; Rahman, F; Ramachandran, R; Raman, B; Sakthivel, MR; Selvakumar, N; Shanmugam, G; Venkatesan, P	1
Chan Kim, K; Choi, JC; Choi, SB; Choi, WI; Heo, EY; Hwang, YI; Jang, SH; Jeon, K; Jung, KH; Kang, YA; Ki, YW; Kim, KU; Kim, SJ; Kim, YH; Koh, WJ; Kwon, YS; Lee, CH; Lee, J; Lee, JH; Lee, SH; Lee, YS; Ryu, YJ; Shim, TS; Um, S; Yim, JJ; Yoo, KH	1
Schluger, NW	1
Gratz, J; Heysell, SK; Houpt, ER; Kibiki, GS; Kumburu, H; Mpagama, SG; Ndusilo, N; Peloquin, CA; Stroup, S	1
Cailleaux-Cezar, M; Chaisson, RE; Conde, MB; Efron, A; Luiz, RR; Mexas, F	1
Ajbani, K; Catanzaro, A; Caviedes, L; Coronel, J; Crudu, V; Desmond, E; Eisenach, K; Ganiats, TG; Garfein, RS; Groessl, EJ; Jackson, RL; Klages, S; Moore, D; Rodrigues, C; Rodwell, TC; Romancenco, E; Trollip, AP; Victor, T; Vineet, VP	1
Elkington, PT; Friedland, JS; Gardiner, H; Kubler, A; Prasad, R; Singh, A; Singh, S; Singh, UK	1
Allaudeen, IS; Chinnaiyan, P; Chockalingam, C; Dhanaraj, B; Dharuman, K; Elangovan, T; Jayabal, L; Kandasamy, C; Kumar, V; Marimuthu, MK; Nair, D; Narasimhan, M; Navaneethapandian, GP; Paramasivam, PK; Perumal, V; Rathinam, P; Rathinam, S; Santhanakrishnan, RK; Shaheed, JM; Sivaramakrishnan, GN; Swaminathan, S; Vadivelu, G; Velayutham, BV	1
Crook, AM; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Murray, SR; Nunn, AJ; Pappas, F; Phillips, PP	1
Chiang, CY; Madan, J; Meredith, SK; Nunn, AJ; Phillips, PP; Rusen, ID; Squire, SB; Torrea, G; Van Deun, A	1
de Droogh, E; Groenen, G; Mathys, V; Soetaert, K; van de Vyvere, M	1
Bateson, AL; Butcher, PD; Charalambous, S; Churchyard, GJ; Clouting, HE; Coleman, D; Geldenhuys, H; Harrison, TS; Hatherill, M; Jindani, A; Magweta, L; McHugh, TD; McIlleron, HM; Mitchison, DA; Mungofa, S; Nunn, AJ; Nyirenda, S; Phillips, PP; Shah, NA; Shepherd, J; van Dijk, JH; Zizhou, S; Zvada, SP	1
Mizrahi, V; Warner, DF	1
Migliori, GB; Sotgiu, G	1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F	1
Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC	1
Converse, PJ; Irwin, SM; Lenaerts, AJ; Li, SY; Mdluli, KE; Nuermberger, EL	1
Chen, Z; Feng, SS; Liang, JQ; Wang, JH; Zhang, GY	1
Kassen, B; Rush, B; Stenstrom, R; Wormsbecker, A	1
Boutou, A; Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Papaioannou, M; Zarogoulidis, K	1
Huh, HJ; Jeon, K; Jeong, BH; Koh, WJ; Lee, H; Lee, NY; Park, HY	1
Gillespie, SH	1
Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM	1
Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C	1
Chen, S; Dong, L; Huang, H; Köser, CU; Moradigaravand, D; Parkhill, J; Peacock, SJ; Schön, T; Shang, Y; Wang, G; Wei, G; Yu, X	1
Darley, DR; Glanville, AR; Goeman, EE; Jensen, TO; Marriott, DJ; Shaw, K	1
Blackmore, T; McNaughton, A; McNaughton, H	1
Karak, A; Mukhopadhay, S; Paul, R; Santra, G	1
Aarnoutse, R; Boeree, MJ; Charalambous, S; Churchyard, G; Colbers, A; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; Heinrich, N; Henne, S; Hoelscher, M; Hunt, RD; Kibiki, GS; Manyama, C; Mekota, A; Minja, LT; Mpagama, SG; Mtafya, B; Narunsky, K; Ntinginya, NE; Phillips, PPJ; Rehal, S; Reither, K; Sanne, I; Semvua, HH; van Balen, GP; Venter, A; Wallis, RS	1
Adamson, J; Chirehwa, M; Denti, P; Essack, S; Govender, K; Kimba-Phongi, E; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N; Yende-Zuma, N	1
Rieder, HL	1
Bishai, WR; Cezar, MC; Chaisson, RE; Chaudhary, MA; Conde, MB; De Souza, GR; Efron, A; Graça, NP; Kritski, AL; Loredo, C; Ram, M	1
Bernardo, J; Bozeman, L; Chaisson, RE; Choudhri, S; Dorman, SE; Goldberg, S; Grosset, JH; Guy, E; Guyadeen, P; Heilig, CM; Johnson, JL; Leus, MC; Maltas, G; Menzies, D; Muzanye, G; Nuermberger, EL; Padayatchi, N; Vernon, A; Villarino, M	1
Chang, KC; Leung, CC	1
Bergmann, JF; Delcey, V; Raskine, L; Sanson-Le-Pors, MJ; Sellier, P	1
Mohapatra, PR	1
Hsu, CL; Hsueh, PR; Lee, LN; Tsai, TH; Wang, JT; Wang, JY; Yang, PC; Yu, CJ	1
Aarnoutse, RE; Alffenaar, JW; Kosterink, JG; Pranger, AD; Uges, DR; van Altena, R; van der Werf, TS; van Soolingen, D	1
Barry, CE; Dartois, V; Goh, A; Prideaux, B; Staab, D; Stoeckli, M; Via, LE; Weiner, DM	1
Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D	1
Fouad, M; Gallagher, JC	1
Abbate, E; Ambroggi, M; Cufré, M; García, A; Gonzalez Montaner, P; Natiello, M; Ritacco, V; van Soolingen, D; Vescovo, M	1
Balasubramanian, V; Deshpande, A; Drusano, GL; Ganguly, S; Gaonkar, S; Kumar, N; Louie, A; Mahesh Kumar, KN; Panduga, V; Reddy, J; Shandil, RK; Solapure, S; Vishwas, KG	1
Denti, P; Geldenhuys, H; Hanekom, W; Harrison, T; Hatherill, M; Jindani, A; McIlleron, HM; Meredith, S; Simonsson, US; van As, D; Wiesner, L; Zvada, SP	1
Fu, L; Jin, H; Li, P; Lu, Y; Mdluli, K; Upton, AM; Wang, B; Xu, J; Zhao, W; Zheng, M; Zhu, H	1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Mendel, CM; Spigelman, MK; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F; Winter, H	1
Bukatina, AA; Galkina, KY; Isaeva, YD; Makarova, MV; Moroz, AM; Nosova, EY	1
Barbui, AM; Garazzino, S; Luccoli, L; Raffaldi, I; Scolfaro, C; Tovo, PA	1
Bellanova, S; Bracciale, P; Legari, G; Manisco, V; Quitadamo, M; Valerio, G	1
Bongard, E; Gillespie, SH; Gosling, RD; Kanduma, EG; Morris, RW; Nyindo, M; Sam, NE; Uiso, LO	1
De Roux, A; Lode, H; Mauch, H; Neumann, KH; Pletz, MW; Roth, A	1
Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; O'Brien, RJ; Rosenthal, I; Tyagi, S; Vernon, AA; Williams, K; Yoshimatsu, T	1
Cokolova, GB; Elistratova, NA; Lazareva, IaV; Mozhokina, GN; Perel'man, MI; Strekchev, AIu	1
Bishai, WR; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, K	2
Gillespie, SH; Gosling, RD; Kanduma, EG; McHugh, TD; Sam, NE; Uiso, L	1
Drobniewski, FA; Krüüner, A; Yates, MD	1
Burman, WJ; Chaisson, RE; Choudhri, S; Daley, CL; Engle, M; Goldberg, S; Johnson, JL; Mosher, AW; Munsiff, SS; Muzanye, G; Vernon, A; Zhao, Z	1
Boom, WH; Charlebois, ED; Daley, CL; Debanne, SM; Dietze, R; Eisenach, KD; Hadad, DJ; Jankus, DD; Johnson, JL; Maciel, E; Palaci, M; Peloquin, CA	1
Chau, CH; Wong, HY; Yew, WW	1
Aarnoutse, RE; Alisjahbana, B; Burger, DM; Nijland, HM; Ruslami, R; Suroto, AJ; van Crevel, R	1
Almeida, D; Grosset, JH; Nuermberger, E; Rosenthal, I; Tasneen, R; Tyagi, S; Williams, KN	1
Agafonov, AP; Azaev, MSh; Blinov, VM; Bodnev, SA	1
Bishai, WR; Chaisson, RE; Chen, JM; Miyazaki, E; Miyazaki, M	1

Reviews

12 review(s) available for moxifloxacin and Tuberculosis, Pulmonary

Article	Year
Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis. The Journal of pharmacy and pharmacology, 2022, Jun-09, Volume: 74, Issue:6 Topics: Antitubercular Agents; Bayes Theorem; Drug Therapy, Combination; Humans; Moxifloxacin; Network Meta-Analysis; Rifampin; Tuberculosis, Pulmonary	2022
The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis. Medicine, 2022, Sep-23, Volume: 101, Issue:38 Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Network Meta-Analysis; Tuberculosis; Tuberculosis, Pulmonary	2022
Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults. Medicine, 2020, Jun-19, Volume: 99, Issue:25 Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Moxifloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2020
Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials. Annals of palliative medicine, 2021, Volume: 10, Issue:2 Topics: Anti-Bacterial Agents; Fluoroquinolones; Humans; Moxifloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary	2021
The first report of co-existence of pulmonary tuberculosis and lung malignancy in a kidney transplant recipient: a case report and literature review. BMC infectious diseases, 2021, Jul-01, Volume: 21, Issue:1 Topics: Adenocarcinoma; China; Ethambutol; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Isoniazid; Kidney Transplantation; Lung; Lung Neoplasms; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Positron Emission Tomography Computed Tomography; Thoracic Surgery, Video-Assisted; Treatment Outcome; Tuberculosis, Pulmonary	2021
Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 60 Topics: Antitubercular Agents; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Recurrence; Sputum; Treatment Outcome; Tuberculosis, Pulmonary	2017
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet (London, England), 2018, 09-08, Volume: 392, Issue:10150 Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2018
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. Drugs, 2019, Volume: 79, Issue:2 Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Treatment Outcome; Tuberculosis, Pulmonary	2019
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:7 Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Molecular Structure; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary	2013
Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis. Tuberculosis (Edinburgh, Scotland), 2015, Volume: 95, Issue:4 Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Odds Ratio; Remission Induction; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary	2015
The role of moxifloxacin in tuberculosis therapy. European respiratory review : an official journal of the European Respiratory Society, 2016, Volume: 25, Issue:139 Topics: Animals; Antibiotics, Antitubercular; Drug Repositioning; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Lung; Moxifloxacin; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2016
Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis. The Annals of pharmacotherapy, 2011, Volume: 45, Issue:11 Topics: Animals; Anti-Infective Agents; Aza Compounds; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fluoroquinolones; Humans; Moxifloxacin; Prospective Studies; Quinolines; Randomized Controlled Trials as Topic; Retrospective Studies; Tuberculosis, Pulmonary	2011

Trials

30 trial(s) available for moxifloxacin and Tuberculosis, Pulmonary

Article	Year
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:3 Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Brazil; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis, Pulmonary	2008
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11 Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Rifampin; Safety; Tuberculosis, Pulmonary; Young Adult	2008
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3 Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary	2023
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. The New England journal of medicine, 2022, 12-22, Volume: 387, Issue:25 Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Linezolid; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2022
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxaci Trials, 2023, Jun-06, Volume: 24, Issue:1 Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Linezolid; Moxifloxacin; Oxazolidinones; Treatment Outcome; Tuberculosis, Pulmonary	2023
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary clinical trials, 2020, Volume: 90 Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Equivalence Trials as Topic; Ethambutol; Female; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Pulmonary; Young Adult	2020
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. The New England journal of medicine, 2021, 05-06, Volume: 384, Issue:18 Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Child; Confidence Intervals; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Pulmonary; Young Adult	2021
A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomized, Controlled Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 01-01, Volume: 70, Issue:1 Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Pharmaceutical Preparations; Treatment Outcome; Tuberculosis, Pulmonary	2020
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13 Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PloS one, 2013, Volume: 8, Issue:7 Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Recurrence; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult	2013
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. American journal of respiratory and critical care medicine, 2013, Oct-01, Volume: 188, Issue:7 Topics: Adult; Aged; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Republic of Korea; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2013
Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Nov-15, Volume: 59, Issue:10 Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Humans; India; Male; Middle Aged; Moxifloxacin; Radiography, Thoracic; Registries; Risk Factors; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult	2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2014
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 2014, Sep-09, Volume: 15 Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Moxifloxacin; Prothionamide; Pyrazinamide; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2014
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2015
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PloS one, 2016, Volume: 11, Issue:5 Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary	2016
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1 Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Ethylenediamines; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Rifampin; South Africa; Tanzania; Tuberculosis, Pulmonary	2017
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5 Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; HIV Infections; Humans; Male; Moxifloxacin; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis, Pulmonary	2017
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670 Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Kaplan-Meier Estimate; Logistic Models; Male; Moxifloxacin; Multivariate Analysis; Pyrazinamide; Quinolines; Rifampin; Sputum; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary	2009
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. American journal of respiratory and critical care medicine, 2009, Aug-01, Volume: 180, Issue:3 Topics: Adult; Antitubercular Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Follow-Up Studies; Humans; Isoniazid; Male; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Pulmonary	2009
Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2010, Volume: 14, Issue:1 Topics: Adult; Aged; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Proportional Hazards Models; Prospective Studies; Quinolines; Sputum; Taiwan; Time Factors; Tuberculosis, Pulmonary	2010
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8 Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis, Pulmonary	2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846 Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Prospective Studies; Pyrazinamide; Quinolines; Sputum; Tuberculosis, Pulmonary; Young Adult	2012
The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. American journal of respiratory and critical care medicine, 2003, Dec-01, Volume: 168, Issue:11 Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Aza Compounds; Female; Fluoroquinolones; Humans; Inhibitory Concentration 50; Isoniazid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Sputum; Tuberculosis, Pulmonary	2003
Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:3 Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Female; Fluoroquinolones; Humans; Isoniazid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Prospective Studies; Quinolines; Sputum; Tuberculosis, Pulmonary	2004
[Optimization of tuberculosis complex chemotherapy with the use of moxifloxacin]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2004, Volume: 49, Issue:6 Topics: Adolescent; Adult; Animals; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Mice; Middle Aged; Moxifloxacin; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary	2004
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. American journal of respiratory and critical care medicine, 2006, Aug-01, Volume: 174, Issue:3 Topics: Adult; Africa; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Sputum; Tuberculosis, Pulmonary; United States	2006
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2006, Volume: 10, Issue:6 Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Single-Blind Method; Tuberculosis, Pulmonary	2006
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Oct-15, Volume: 45, Issue:8 Topics: Adolescent; Adult; Antibiotics, Antitubercular; Aza Compounds; Drug Interactions; Female; Fluoroquinolones; Humans; Indonesia; Isoniazid; Male; Middle Aged; Moxifloxacin; Plasma; Quinolines; Rifampin; Tuberculosis, Pulmonary	2007

Other Studies

68 other study(ies) available for moxifloxacin and Tuberculosis, Pulmonary

Article	Year
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Drug Synergism; Female; Lung; Mice; Organ Size; Pyrazinamide; Quinolines; Spleen; Survival Analysis; Tuberculosis, Pulmonary	2007
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary	2008
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; Ethambutol; Fluoroquinolones; Immunocompetence; Inhalation Exposure; Isoniazid; Linezolid; Mice; Mice, Inbred C57BL; Moxifloxacin; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Rifampin; Tuberculosis, Pulmonary	2010
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. Journal of medicinal chemistry, 2014, Jun-12, Volume: 57, Issue:11 Topics: Acute Disease; Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Biological Availability; Chronic Disease; DNA Gyrase; Drug Resistance, Bacterial; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Macrophages; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Mutation; Mycobacterium tuberculosis; Piperidines; Protein Subunits; Rats; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tuberculosis, Pulmonary	2014
Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. Bioorganic & medicinal chemistry letters, 2022, 09-15, Volume: 72 Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR. Morbidity and mortality weekly report, 2022, Feb-25, Volume: 71, Issue:8 Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Pulmonary; United States	2022
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis. International journal of environmental research and public health, 2022, 04-15, Volume: 19, Issue:8 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Pneumonia; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary	2022
Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2022, May-04, Volume: 93, Issue:1 Topics: Antitubercular Agents; Fluoroquinolones; Humans; Moxifloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Case report: A 9-year systematic treatment failure of a pulmonary tuberculosis patient. Frontiers in public health, 2022, Volume: 10 Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Treatment Failure; Tuberculosis, Pulmonary	2022
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials. The Lancet. Microbe, 2023, Volume: 4, Issue:11 Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Microbiota; Moxifloxacin; Retrospective Studies; RNA, Ribosomal, 16S; Sputum; Tanzania; Tuberculosis; Tuberculosis, Pulmonary	2023
Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis. Antimicrobial agents and chemotherapy, 2019, 12-20, Volume: 64, Issue:1 Topics: Antitubercular Agents; Cell Line; Computer Simulation; Decision Support Techniques; Drug Development; Fluoroquinolones; Humans; Macrophages; Models, Biological; Monte Carlo Method; Moxifloxacin; Mycobacterium tuberculosis; THP-1 Cells; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2019
Tuberculosis treatment: one-shot approach or cascade of regimens? The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2020
Moxifloxacin induced encephalopathy in disseminated tuberculosis: A case report. The Indian journal of tuberculosis, 2020, Volume: 67, Issue:3 Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Deprescriptions; Discitis; Electroencephalography; Encephalitis; Humans; Male; Moxifloxacin; Neurotoxicity Syndromes; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tuberculosis, Spinal	2020
Efficacy of moxifloxacin combined with levofloxacin in the treatment of drug-resistant tuberculosis. Pakistan journal of pharmaceutical sciences, 2020, Volume: 33, Issue:3(Special) Topics: Adult; Antibiotics, Antitubercular; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Random Allocation; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2020
First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant The American journal of tropical medicine and hygiene, 2017, Volume: 96, Issue:5 Topics: Adult; Aged; Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Genes, Bacterial; Humans; Kanamycin; Male; Microbial Sensitivity Tests; Molecular Typing; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Retrospective Studies; Risk Factors; Saudi Arabia; Tandem Repeat Sequences; Tuberculosis, Pulmonary	2017
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary	2017
A novel presentation of Mycobacterium avium complex in a recipient of a lung transplant: a case report. Journal of medical case reports, 2017, Aug-28, Volume: 11, Issue:1 Topics: Aged; Antitubercular Agents; Ethambutol; Female; Fluoroquinolones; Graft Rejection; Humans; Immunosuppressive Agents; Lung; Lung Transplantation; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Prednisone; Pulmonary Fibrosis; Rifampin; Tacrolimus; Tomography, X-Ray Computed; Tuberculosis, Pulmonary	2017
Tuberculosis in recipients of solid-organ transplants during 1995-2015 in Cali, Colombia. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 11-01, Volume: 21, Issue:11 Topics: Adolescent; Adult; Antitubercular Agents; Colombia; Female; Fluoroquinolones; Graft Rejection; Humans; Male; Middle Aged; Moxifloxacin; Opportunistic Infections; Organ Transplantation; Retrospective Studies; Rifampin; Risk Factors; Sputum; Transplant Recipients; Treatment Outcome; Tuberculosis; Tuberculosis, Pulmonary; Young Adult	2017
Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. The Journal of antimicrobial chemotherapy, 2018, 02-01, Volume: 73, Issue:2 Topics: Adult; Antitubercular Agents; Female; Georgia (Republic); Humans; Lung; Male; Microdialysis; Middle Aged; Moxifloxacin; Serum; Topoisomerase II Inhibitors; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2018
Antituberculosis Treatment in a Patient with Celiac Disease. Archivos de bronconeumologia, 2018, Volume: 54, Issue:6 Topics: Aged; Antitubercular Agents; Celiac Disease; Diarrhea; Diet, Gluten-Free; Drug Compounding; Drug Substitution; Drug Therapy, Combination; Ethambutol; Glutens; Hemoptysis; Humans; Isoniazid; Male; Metronidazole; Moxifloxacin; Pyrazinamide; Rifampin; Smoking; Tomography, X-Ray Computed; Tuberculosis, Pulmonary	2018
Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Jun-15, Volume: 118 Topics: Aerosols; Antitubercular Agents; Cell Line; Cell Survival; Chemistry, Pharmaceutical; Drug Combinations; Drug Stability; Fluoroquinolones; Humans; Moxifloxacin; Powders; Pyrazinamide; Tuberculosis, Pulmonary	2018
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:7 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Tuberculosis, Pulmonary	2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC infectious diseases, 2018, 07-11, Volume: 18, Issue:1 Topics: Adult; Antitubercular Agents; Clinical Protocols; Ethambutol; Female; HIV Seropositivity; Humans; Incidence; Isoniazid; Male; Moxifloxacin; Treatment Outcome; Tuberculosis, Pulmonary	2018
Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for Frontiers in immunology, 2019, Volume: 10 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Granuloma; Hematopoietic Stem Cell Transplantation; Humans; Lung; Male; Mice; Mice, Inbred C57BL; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis, Pulmonary	2019
Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India. The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1 Topics: Adult; Antitubercular Agents; Cardiotoxicity; Clofazimine; Cycloserine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Ethionamide; Female; Humans; India; Linezolid; Male; Moxifloxacin; National Health Programs; Sputum; Time Factors; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Moxifloxacin; Ofloxacin; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2019
Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China. International journal of antimicrobial agents, 2019, Volume: 54, Issue:5 Topics: Antitubercular Agents; Capreomycin; China; Clofazimine; Drug Synergism; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Fluoroquinolones in the treatment of tuberculosis: which is best? American journal of respiratory and critical care medicine, 2013, Oct-01, Volume: 188, Issue:7 Topics: Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Quinolines; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2013
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2 Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Sputum; Tanzania; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2014
Understanding and retention of trial-related information among participants in a clinical trial after completing the informed consent process. Clinical trials (London, England), 2014, Volume: 11, Issue:1 Topics: Adult; Antitubercular Agents; Brazil; Comprehension; Developing Countries; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Informed Consent; Male; Middle Aged; Moxifloxacin; Randomized Controlled Trials as Topic; Retention, Psychology; Rifampin; Surveys and Questionnaires; Tuberculosis, Pulmonary	2014
Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:2 Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; India; Kanamycin; Microbial Sensitivity Tests; Microscopy; Moldova; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Peru; Predictive Value of Tests; Reproducibility of Results; South Africa; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2014
Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8 Topics: Antitubercular Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Epithelial Cells; Fibroblasts; Fluoroquinolones; Humans; Isoenzymes; Isoniazid; Lung; Matrix Metalloproteinases; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Primary Cell Culture; Rifampin; Stromal Cells; Tuberculosis, Pulmonary	2014
False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:10 Topics: Aged; Amikacin; Amino Acid Sequence; Antibiotics, Antitubercular; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Fluoroquinolones; Genotype; Humans; Isoniazid; Male; Molecular Sequence Data; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Phenotype; Pyrazinamide; Rifampin; Sensitivity and Specificity; Sputum; Tuberculosis, Pulmonary	2014
Shortening treatment for tuberculosis--to basics. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Antitubercular Agents; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Pulmonary	2014
New effective antituberculosis regimens. Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study. The European respiratory journal, 2015, Volume: 46, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult	2015
Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:7 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Colony Count, Microbial; Fluoroquinolones; Lung; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Moxifloxacin; Recurrence; Species Specificity; Treatment Outcome; Tuberculosis, Pulmonary	2015
Moxifloxacin Use and Its Association on the Diagnosis of Pulmonary Tuberculosis in An Inner City Emergency Department. The Journal of emergency medicine, 2016, Volume: 50, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Delayed Diagnosis; Emergency Service, Hospital; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Retrospective Studies; Tuberculosis, Pulmonary	2016
Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:11 Topics: Adult; Aged; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Greece; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Outpatients; Rifampin; Tuberculosis, Pulmonary	2015
Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2016
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9 Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary	2016
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9 Topics: Antitubercular Agents; China; DNA Gyrase; Drug Dosage Calculations; Drug Resistance, Bacterial; Fluoroquinolones; Gene Expression; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Pulmonary	2016
Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection. Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:5 Topics: Adult; Allografts; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antitubercular Agents; Bacteremia; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Immunosuppression Therapy; Isoniazid; Latent Tuberculosis; Lung Transplantation; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pseudomonas aeruginosa; Rifampin; Tissue Donors; Tuberculosis, Pulmonary	2016
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand. The European respiratory journal, 2016, Volume: 48, Issue:4 Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary	2016
Gitelman-like Syndrome with Kanamycin Toxicity. The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:5 Topics: Adult; Alkalosis; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Hypokalemia; Kanamycin; Moxifloxacin; Muscle Cramp; Potassium; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2016
Fourth-generation fluoroquinolones in tuberculosis. Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670 Topics: Anti-Infective Agents; Aza Compounds; Drug Administration Schedule; Drug Discovery; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Sputum; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2009
Moxifloxacin versus ethambutol in initial tuberculosis treatment. Lancet (London, England), 2009, Jun-27, Volume: 373, Issue:9682 Topics: Analysis of Variance; Antitubercular Agents; Aza Compounds; Ethambutol; Fluoroquinolones; Humans; Logistic Models; Moxifloxacin; Odds Ratio; Quinolines; Sputum; Tuberculosis, Pulmonary	2009
Moxifloxacin versus ethambutol in initial tuberculosis treatment. Lancet (London, England), 2009, Jun-27, Volume: 373, Issue:9682 Topics: Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Ethambutol; Fluoroquinolones; Humans; Medication Adherence; Moxifloxacin; Patient Selection; Practice Guidelines as Topic; Quinolines; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2009
Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug? American journal of respiratory and critical care medicine, 2009, Oct-01, Volume: 180, Issue:7 Topics: Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2009
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. The European respiratory journal, 2011, Volume: 38, Issue:4 Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Drug Interactions; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Netherlands; Quinolines; Retrospective Studies; Treatment Outcome; Tuberculosis, Pulmonary	2011
High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Analytical chemistry, 2011, Mar-15, Volume: 83, Issue:6 Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Female; Fluoroquinolones; Granuloma, Respiratory Tract; Lung; Molecular Imaging; Moxifloxacin; Quinolines; Rabbits; Reference Standards; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tuberculosis, Pulmonary	2011
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Disease Models, Animal; Drug Administration Schedule; Female; Fluoroquinolones; Granuloma; Humans; Isoniazid; Lung; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rabbits; Rifampin; Tissue Extracts; Tuberculosis, Pulmonary	2012
Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:2 Topics: Acetamides; Adult; Antitubercular Agents; Argentina; Aza Compounds; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Humans; Linezolid; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Oxazolidinones; Quinolines; Retrospective Studies; Thioridazine; Treatment Outcome; Tuberculosis, Pulmonary	2012
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Animals; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis, Pulmonary	2012
In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2012, Volume: 16, Issue:8 Topics: Animals; Antitubercular Agents; Aza Compounds; Chronic Disease; Clofazimine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Isoniazid; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Time Factors; Tuberculosis, Pulmonary	2012
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. Journal of medical microbiology, 2013, Volume: 62, Issue:Pt 1 Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Russia; Tuberculosis, Pulmonary	2013
Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience. Pediatric pulmonology, 2014, Volume: 49, Issue:4 Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Female; Fluoroquinolones; Humans; Infant; Male; Moxifloxacin; Prospective Studies; Tuberculosis, Pulmonary	2014
Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:1 Topics: Aged; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Quinolines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary	2003
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. American journal of respiratory and critical care medicine, 2004, Nov-15, Volume: 170, Issue:10 Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Multivariate Analysis; Quinolines; Random Allocation; Reference Values; Sensitivity and Specificity; Tuberculosis, Pulmonary	2004
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. American journal of respiratory and critical care medicine, 2005, Dec-01, Volume: 172, Issue:11 Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary	2005
Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. The Journal of antimicrobial chemotherapy, 2005, Volume: 56, Issue:6 Topics: Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Sputum; Tuberculosis, Pulmonary	2005
Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. Journal of clinical microbiology, 2006, Volume: 44, Issue:3 Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis, Pulmonary	2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary	2006
Moxifloxacin-induced arthropathy. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2007, Volume: 11, Issue:1 Topics: Aged, 80 and over; Antitubercular Agents; Arthritis; Aza Compounds; Drug Therapy, Combination; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary	2007
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Pulmonary	2008
[Study of antituberculous activity of moxifloxacin conjugate with macrophage scavenger-receptor ligand]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2006, Volume: 51, Issue:11-12 Topics: Animals; Antitubercular Agents; Aza Compounds; beta-Glucans; Cells, Cultured; Fluoroquinolones; Humans; Ligands; Macrophage Activation; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Receptors, Scavenger; Tuberculosis, Pulmonary	2006
Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:1 Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Drug Resistance, Microbial; Female; Fluoroquinolones; Half-Life; Lung; Mice; Moxifloxacin; Organ Size; Quinolines; Spleen; Time Factors; Tuberculosis, Pulmonary	1999